Vivos Therapeutics, Inc. (VVOS) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, Vivos Therapeutics reported revenue of $17.4M, up 16.0% from $15.0M the year before. Net income was -$21.2M (a -121.4% net margin), or -$2.07 per diluted share. Gross margin was 60.4% and operating margin was -114.1%. Operating activities generated -$15.3M of cash, leaving -$17.6M of free cash flow. At fiscal year end, Vivos Therapeutics held $25.2M in total assets against $26.7M in total liabilities, including $2.0M of cash and equivalents.
Open the full interactive Vivos Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Vivos Therapeutics Key Stats
| Share Price | $0.14 |
|---|---|
| Market Cap | $2.5M |
| Revenue YoY Growth | +16.1% |
| 52-Week Range | $0.13 – $3.18 |
| Shares Outstanding | 17.7 million (basic, 2026 Q2) |
Vivos Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $13.1M | $16.9M | $16.0M | $13.8M | $15.0M | $17.4M |
| Cost of Goods Sold | — | $100,000 | $100,000 | $200,000 | — | — |
| Gross Profit | $10.4M | $12.6M | $10.0M | $8.3M | $9.0M | $10.5M |
| Operating Income | -$12.0M | -$20.4M | -$25.0M | -$17.3M | -$11.2M | -$19.9M |
| Pre-Tax Income | -$12.1M | -$20.3M | -$23.8M | -$13.6M | -$11.1M | -$21.2M |
| Income Tax | — | — | — | — | — | -$60,000 |
| Net Income | -$12.1M | -$20.3M | -$23.8M | -$13.6M | -$11.1M | -$21.2M |
| Diluted EPS | -$35.00 | -$24.00 | — | -$11.14 | -$2.22 | -$2.07 |
Vivos Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $6.8M | $3.8M | $5.1M | $5.2M |
| Net Income | -$5.4M | -$6.9M | -$7.7M | -$5.5M |
| Diluted EPS | -$0.49 | -$0.67 | -$0.52 | -$0.31 |
Vivos Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $18.2M | $24.0M | $3.5M | $1.6M | $6.3M | $2.0M |
| Current Assets | $20.4M | $27.3M | $5.4M | $2.5M | $7.5M | $4.4M |
| Total Assets | $25.3M | $33.7M | $13.7M | $10.7M | $15.3M | $25.2M |
| Current Liabilities | $7.8M | $7.5M | $6.8M | $7.3M | $5.0M | $18.1M |
| Total Long-Term Debt | $1.3M | $2.5M | — | $1.2M | $1.2M | $8.8M |
| Total Liabilities | $8.4M | $8.2M | $8.9M | $10.3M | $7.3M | $26.7M |
| Shareholders' Equity | $16.9M | $25.5M | $4.8M | $411,000 | $8.0M | -$1.5M |
Vivos Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$5.7M | -$15.7M | -$19.6M | -$11.9M | -$12.7M | -$15.3M |
| Cash From Investing | -$120,252 | -$2.6M | -$924,000 | -$853,000 | -$568,000 | -$7.5M |
| Cash From Financing | $23.5M | $24.2M | — | $10.9M | $17.9M | $18.6M |
| Free Cash Flow | -$5.8M | -$18.1M | -$20.5M | -$12.7M | -$13.3M | -$17.6M |
Figures from Vivos Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Vivos Therapeutics financials page for every line item.
Vivos Therapeutics Company Profile
| Ticker | VVOS |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Littleton, Colorado |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001716166 |
Frequently Asked Questions
What was Vivos Therapeutics' revenue in fiscal 2025?
Vivos Therapeutics (VVOS) reported revenue of $17.4M for fiscal 2025.
What is Vivos Therapeutics' annual revenue history?
Vivos Therapeutics' annual revenue by fiscal year: 2020: $13.1M; 2021: $16.9M; 2022: $16.0M; 2023: $13.8M; 2024: $15.0M; 2025: $17.4M.
What was Vivos Therapeutics' net income in fiscal 2025?
Vivos Therapeutics reported net income of -$21.2M for fiscal 2025.
What was Vivos Therapeutics' earnings per share (EPS) in fiscal 2025?
Vivos Therapeutics' diluted EPS was -$2.07 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Vivos Therapeutics generate in fiscal 2025?
Vivos Therapeutics generated -$17.6M of free cash flow in fiscal 2025.
What was Vivos Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Vivos Therapeutics reported revenue of $5.2M.
How much debt does Vivos Therapeutics have?
Vivos Therapeutics reported $8.8M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Vivos Therapeutics are outstanding?
Vivos Therapeutics reported a weighted average of 17.7 million basic shares outstanding in 2026 Q2.
What is Vivos Therapeutics' market cap?
Based on its latest closing price, Vivos Therapeutics (VVOS) has a market capitalization of about $2.5M.
When does Vivos Therapeutics' fiscal year end?
Vivos Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Vivos Therapeutics headquartered?
Vivos Therapeutics lists its business address in Littleton, Colorado in its SEC filings.
Vivos Therapeutics Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →